Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer

Breast Cancer Clinical Trial

— mp-BUS  

Official title:

Multi-parametric Breast Ultrasound Imaging as a Potential Biomarker for Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04480437
• Other study ID #: 2020-01-mp-BUS
• Status: Completed
• Phase: N/A
• Start date: November 15, 2020
• Est. completion date: December 13, 2021

Study information

• Verified date: December 2021
• Source: Swiss Federal Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

It is studied whether multi-parametric biomarkers such as speed-of-sound imaging or others, applied during breast ultrasound (BUS) imaging allows to classify lesions according to its malignancy. The standard reference intervention is BUS guided biopsy or the consensus of the board of experts judging the BUS imaging results if no biopsy is done.

Description:

Patients with a palpable lump in the breast or suspicious findings in X-ray mammography typically undergo breast ultrasound examination as a supplemental imaging modality. Findings are then used for tumour classification according the American Collage of Radiology (ACR) Breast Imaging Reporting and Database System (BI-RADS) lexicon. Suspicious findings then undergo ultrasound-guided biopsy, which causes discomfort for the patient and introduces high emotional stress, and may involve - albeit very-small - risk of complications (such as bleeding and infections).

Today conventional breast ultrasound B-mode images do not have the specificity to reliably differentiate malignant and benign tissues in all cases and hence a biopsy intervention or close follow-up is necessitated. Multiparametric imaging bio-markers such as the novel method of speed-of-sound imaging may provide additional indicators to help to better classify lesions prior to biopsy and avoid any further work-up.

The study collects data with an ultrasound device during normal BUS examination which is then retrospectively processed to extract the desired multi-parametric BUS (mp-BUS) information of imaged tissue.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 13, 2021
• Est. primary completion date: December 13, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women who are suspected or suspected of having breast cancer and who are advised to perform a detailed breast ultrasound or tissue sampling (biopsy)

• Classification into groups:

• Group 1: Foreseen for BUS guided biopsy

• Group 2: BI-RADS classification I, II and III and foreseen for BUS only based diagnosis

Exclusion Criteria:

• Lactating women

• Women with mastitis

• Vulnerable persons

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• mp-BUS data collection
Collect ultrasound raw data and B-mode images of all kind of breast lesions to external storage device.

Locations

Country	Name	City	State
Switzerland	Kantonsspital Baden	Baden

Sponsors (2)

Lead Sponsor	Collaborator
Swiss Federal Institute of Technology	Kantonsspital Baden

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Speed-of-sound imaging shows malignancy of lesion	Evaluate the non-inferiority or superiority of the multi-parametric method compared to the standard ultrasound technique, using BUS guided biopsy as gold standard, to determine the malignancy of a lesion in woman breast.	6 months